

Treating Thyroid Despite Normal Labs

Jacob Teitelbaum MD and Kent Holtorf MD

The physician consultant opines that only patients with labs outside the normal range should be treated and to give thyroid support when this is not the case is outside of the standard of practice. This was stated despite a large number of studies given showing that this is not the case. This patient likely has a combination of secondary or tertiary and primary hypothyroidism (as discussed below). But, even if there was no central hypothyroidism involved, treatment is indicated.

Clinically, this patient had numerous signs and symptoms of hypothyroidism including:

1. A 40 lb weight gain with inability to lose weight
2. Elevated cholesterol
3. Severe fatigue
4. Periorbital oedema
5. Constipation
6. Severe widespread aches / pain
7. Constipation
8. Arthralgias
9. Cognitive dysfunction
10. Dry skin
11. Paresthesias
12. Slow relaxation phase of the ankle reflex (SRPAR)

In a study published in the *Journal of Endocrinology and Metabolism*, the SRPAR was found in 77% of individuals with tissue hypothyroidism and in only 6.5% of normals; dry skin was found in 76% of individuals with tissue hypothyroidism and in 36.2% of normals; course skin was found in 60% of individuals with tissue hypothyroidism and only 18.8% of normals; periorbital puffiness was found in 60% of individuals with tissue hypothyroidism and only 3.7% of normals; constipation was found in 48% of individuals with tissue hypothyroidism and only 15% of normals; and constipation was found in 48% of individuals with tissue hypothyroidism and only 15% of normals (150). The combination of these signs and symptoms is highly specific for the presence of thyroid dysfunction and a diminished end-organ thyroid effect. Another study published in the *British Medical Journal* also found that SRPAR was a better indicator of tissue hypothyroidism than thyroid function tests (TFT's)(153).

While treatment with thyroid hormone is clearly indicated in this patient and with treatment, the patient would be expected to have symptomatic improvement as well as a reduction of numerous disease risk, this certainly will not, on its own, be effective without addressing the multiple physiologic abnormalities present in CFS.

Numerous studies have demonstrated a central hypothyroidism in the overwhelming majority of patients with FM and CFS. For instance, a study published in the peer reviewed *Journal of Rheumatology* looked at the incidence of central hypothyroidism in patients with FM (6). They found, through the use of thyrotropin releasing hormone (TRH) testing, that all of the patients studied with FM had central hypothyroidism despite having baseline thyroid function tests (TFT's) in the normal range. They found that these patients with central hypothyroidism tended to have low normal TSH levels that averaged 0.86 vs 1.42 in normals with normal free T4 and free T3 levels. The free T4 levels were slightly higher in the patients with central hypothyroidism and the free T3 levels were slightly lower in patients with central hypothyroidism. With appropriate replacement, the TSH is usually low, undetectable or low normal so this is not by itself an indication of hyperthyroidism or over-treatment in this patient population. A TRH stimulation test would have been ideal to perform, but TRH is currently unavailable for clinical use.

Other studies confirm the fact that standard TFT's cannot be used to rule out central hypothyroidism, as they are generally undifferentiable from euthyroid individuals (6,8,119). One such study clearly demonstrating this fact was published in the *Journal of Clinical Endocrinology and Metabolism* where it was determined how often central hypothyroidism went undetected by standard TFT's (119). They found that 92% of patients with central

hypothyroidism would have remained undiagnosed using baseline TFT's. Thus, it is incorrect to conclude that thyroid replacement is not appropriate in this patient if he had TFT's in the normal range. Therefore, the utility of such testing is very low and would not be an effective means of directing treatment.

A study published in *The Lancet* performed thyroid biopsies in patients with chronic fatigue and found that 40% of these patients had lymphocytic thyroiditis, with only half of these being positive for TPO or antithyroglobulin antibodies (thus going undetected). They also found that "clinical response to thyroxine was equally favorable among patients with lymphocytic thyroiditis, irrespective of initial thyrotropin (TSH) concentrations (120)." This demonstrates that many of these patients with CFS and FM have a thyroiditis that is not detectable by standard auto-antibody testing and that such patients respond to thyroid replacement regardless of their baseline TFT's.

Another study published in the *Journal of Chronic Fatigue Syndrome* demonstrated that due to the hypothalamic and pituitary dysfunction present in FM patients, multiple hormone replacement, including thyroid, is appropriate, safe and effective despite baseline levels being in the normal range. Numerous other studies have also been published that support the appropriateness and safety of this treatment (13).

There is controversy as to the usefulness of follow-up TFT's, especially in patients with CFS and central hypothyroidism (13,152,153,119,121,122,123,124,125,154). A study published in the *British Medical Journal* found that for individuals who had overtly abnormal thyroid tests initially, but normal labs with treatment with thyroid replacement, the evaluation of clinical symptoms by doctors experienced in thyroid disease was a more accurate measurement of end-organ thyroid effect than TSH, free T4 or Free T3 levels (151). This is also especially and more certainly true of individuals with any degree of central hypothyroidism as in this case. The authors state, "To establish their role in monitoring patients receiving thyroxine replacement biochemical tests of thyroid function were performed in 148 hypothyroid patients studied prospectively. Measurements of serum concentrations of total thyroxine, analogue free thyroxine, total triiodothyronine, analogue free triiodothyronine, and thyroid stimulating hormone, made with a sensitive immunoradiometric assay, did not, except in patients with gross abnormalities, distinguish euthyroid patients from those who were receiving inadequate or excessive replacement. These measurements are therefore of little, if any, value in monitoring patients receiving thyroxine replacement (151)."

There are additional reasons that baseline and also follow-up TFT's are of limited use in treatment of patients with CFS and FM (127-143). For example, a low TSH does not necessarily indicate excessive thyroid therapy or hyperthyroidism, again showing that the reviewer's insistence that any one who relies on anything except the tests, including clinical signs and symptoms, is practicing outside of the standard of practice. Even in normal individuals without CFS or FM, a suppressed TSH requires clinical correlation. For instance, a study published in the *British Medical Journal* demonstrated that the false positive rate that a suppressed TSH indicates hyperthyroidism in someone on thyroid replacement is 80% (151).

The positive predictive value that a suppressed TSH indicates hyperthyroidism in normal individuals with primary thyroid failure is:

$$\text{Positive predictive value (PPV)} = \frac{\text{sensitivity} \times \text{prevalence}}{((100-\text{specificity}) \times (100-\text{prevalence})) + (\text{sensitivity} \times \text{prevalence})}$$

$$\frac{59 \times 20}{(100-51) \times (100-20) + (59 \times 20)} = 23 \%$$

$$\frac{1180}{49 \times 80 + 1180}$$

Thus, a person on thyroid replacement with a suppressed TSH has only a 23% chance of being hyperthyroid. In addition, if a person has any degree of central hypothyroidism, as in this case, the suppressed TSH is meaningless (127,128,129,139,131,132,133,134,135,136,137,138,139, 140,141,142,143). The most

appropriate and accurate means of monitoring adequate replacement in these patients is a careful assessment of clinical response. For a given level of T4 and T3 in the serum, the pituitary and heart will always have a higher intracellular level of T3 than any other tissue (161,162). This is why the first change with subclinical and frank hyperthyroidism is a suppressed TSH (although meaningless with hypothalamic and pituitary dysfunction seen in CFS and FM) and an increase in heart rate (162,163). Excessive reliance on laboratory values and ignoring the clinical picture can lead to an improper assessment and inaccurate diagnosis.

Blindly treating a lab value without a thought of the underlying pathophysiology or clinical correlation does not exemplify the practice of good medicine. It is for that reason that I analyze the entire picture, identify all of the underlying issues, assess correlation and treat with a multiprong approach for the most effective outcomes.

In addition, it has been shown that these patients with central hypothyroidism secrete a TSH that is less bioactive than normal TSH (127-143,151,152,153). This decreased bioactivity is not detected on 3rd generation or other standard TSH assays. This results in a lower level of T4 and T3 for any given concentration of TSH. This is why the TSH is not reliable in central hypothyroidism and that you must suppress the TSH in order to even begin to achieve tissue euthyroidism (127-143,149,151,152,153). A landmark study by Escobar published in the *Journal of Clinical Investigation* measured the tissue level of T3 in 10 different tissues during T4 thyroid replacement. They found that all tissues except the brain (including the pituitary) required supraphysiologic levels of plasma T4 to provide normal tissue levels of T3. Doses of T4 that normalized plasma T4 and T3 levels were insufficient to normalize the concentration of T3 in most tissues. A notable exception was the brain (pituitary), which showed a remarkable degree of independence from plasma T4 and T3 levels and other tissue concentrations of T4 and T3. As some amounts of T4 infused, the level of thyroid hormones in the pituitary was over twice that of other tissues, again demonstrating that pituitary levels and thus TSH secretion is not an accurate measure of tissue hypothyroidism. The authors conclude, *“It is evident that neither plasma T4 nor plasma T3 levels alone permit prediction of the degree of change in T4 and T3 concentrations in tissues... The current replacement therapy of hypothyroidism should no longer be considered adequate, and might possibly lead to the development of new strategies of therapy...(155)”*

It was originally believed that thyroid hormones enter the cells by passive diffusion, but it is now clear that cellular uptake is via a carrier-mediated process (156,157,158,159) and studies are demonstrating the presence of a thyroid resistance in CFS and FM, possibly secondary to a defect in the transport system, further limiting the utility of TFT's in evaluation of tissue levels of thyroid (121,122,123,124,125,126,165). Consequently, the multiple uncertainties and variables associated with a combination of primary hypothyroidism, central hypothyroidism and thyroid resistance make the most appropriate method of monitoring adequate tissue levels of thyroid a knowledgeable physician's clinical assessment (121-153,165). A number of double blind placebo controlled trials have demonstrated that follow-up TFT's are of little help in determining tissue euthyroidism in these patients and have demonstrated the superiority of clinical assessment over TFT in these patients (123,124,125,126,154,13,165).

Endocrinology texts are clear that if there is any degree of hypothalamic or pituitary dysfunction, as with this patient, the recommended method of monitoring thyroid replacement is by clinical assessment as the TSH is meaningless and should be suppressed with proper dosing (162,165,168).

Footnotes and References

1. Reeves WC, Lloyd A, Vernon SD, Klimas N, Jason LA, Bleijenberg G, Evengard B, White PD, Nisenbaum R, Unger ER, and the International Chronic Fatigue Syndrome Study Group. Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for resolution. *BMC Health Services Research* 2003;3:25.
2. Fukuda K, Straus Se et al. The International Chronic Fatigue Syndrome Study Group. The chronic fatigue syndrome; a comprehensive approach to its definition and study. *Ann Intern Med.* 1994;121:953-959.

3. Komaroff AL, Fagioli LR et al. An Examination of the Working Definition of Chronic Fatigue Syndrome. *The American Journal of Medicine*. January 1996(100):56-64.
4. Demitrack MA, Dale JK, Straus SE, Laue L, Listwak SJ, Kruesi MJP, et al. Evidence For Impaired Activation of the Hypothalamic-Pituitary-Adrenal Axis in Patients With Chronic Fatigue Syndrome. *J Clin Endocrinol Metab* 1991;73:1224-1234.
5. Torpy DJ et al. Responses of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis to interleukin-6 in fibromyalgia. *Arthritis and Rheumatism*. 2000; 43: 872-880.
6. Neeck G, Riedel W. Thyroid Function in Patients with Fibromyalgia Syndrome. *J of Rheumatology* 1992;19-7:1120-1122.
7. Jens Gaab, PhD, Dominik Hüster, MSc, Renate Peisen, MSc, Veronika Engert, BSc, Vera Sheitz, BSc, Tanja Schad, BSc, Thomas H. Schürmeyer, PhD, MD and Ulrike Ehlert, PhD. Hypothalamic-Pituitary-Adrenal Axis Reactivity in Chronic Fatigue Syndrome and Shealth Under Psychological, Physiological, and Pharmacological Stimulation. *Psychosomatic Medicine* 64:951-962 (2002).
8. Lowe JC. Thyroid Status of 38 Fibromyalgia Patients: Implications for the Etiology of Fibromyalgia. *Clin Bull Myofacial Therapy*, 2(1):47-64, 1997.
9. Calis M, Gokce C. Investigation of the hypothalamo-pituitary-adrenal axis (HPA) by 1ug ACTH test and metyrapone test in patients with primary fibromyalgia syndrome. *J Endocrinol Invest* 2004 27:42-46
10. Bennett RM, Cook DM, Clark SR, Burckhardt CS, Campbell SM: Hypothalamic-pituitary-insulin-like growth factor-I axis dysfunction in patients with fibromyalgia. *J.Rsheumatol*. 1997, 24:1384-1389.
11. Adler, Gail K. Hormonal changes and fibromyalgia. *Current Opinion in Endocrinology & Diabetes*. 6(1):55, February 1999.
12. Kirnap M, Colak R, Eser C, Ozsoy O, Tutus A, Kelestimur F. A comparison between low-dose (1 microg), standard-dose (250 microg) ACTH stimulation tests and insulin tolerance test in the evaluation of hypothalamo-pituitary-adrenal axis in primary fibromyalgia syndrome. *Clin Endocrinol (Oxf)*. 2001 Oct;55(4):455-9
13. Teitelbaum J, Bird B, Greenfield R, Weiss A, Muenz L, Gould L. Effective Treatment of Chronic Fatigue Syndrome (CFIDS) & Fibromyalgia (FMS) - A Randomized, Double-Blind, Placebo-Controlled, Intent To Treat Study. *Journal of Chronic Fatigue Syndrome Volume 8, Issue 2 – 2001*.
14. Jones JF, Ray G, Miunick LL, et al: Evidence for active Epstein-Barr virus infection in patients with persistent unexplained illness: elevated early antigen antibodies. *Ann Intern Med* 1985; 102:1-7
15. Jones JF, Armstrong G, et al: Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection. *Ann Intern Med* 1985; 102:7-16
16. Holmes GP, Kaplan JE, StewartJA, et al: A cluster of patients with a chronic mononucleosis-like syndrome, is Epstein-Barr virus the cause? *JAMA* 1987; 257:2297-2302
17. Horwitz CA, Henle W, Henle G, et al: Long-term serological follow-up of patients for Epstein-Barr virus after recovery from infectious mononucleosis. *J Infect Dis* 1985; 151:1150-1153
18. Buchwald D, Sullivan JL, Komaroff AL: Frequency of chronic active Epstein-Barr virus infection" in a general medical practice. *JAMA* 1987; 257:2303-2307

19. Gold D, Bowden R, Sixbey J, et al: Chronic fatigue: a prospective clinical and virologic study. *JAMA* 1990; 264:48-53
20. Kawai K, Kawai A: Studies on the relationship between chronic fatigue syndrome and Epstein-Barr virus in Japan. *Intern Med* 1992; 31:313-318
21. Garth L. Nicolson,¹ PhD, Marwan Y. Nasralla,² PhD, Kenny De Meirleir,³ MD, PhD and Jeorg Haier,⁴ MD, PhD. Bacterial and Viral Co-Infections in Chronic Fatigue Syndrome (CFS/ME) Patients. Proc. Clinical & Scientific Conference on Myalgic Encephalopathy/Chronic Fatigue Syndrome, the Practitioners Challenge, Alison Hunter Foundation, Sydney, Australia 2002
22. Jo Nijs ¹, MSc; Garth L Nicolson ², PhD; Pascale De Becker ¹, PhD; Danny Coomans ⁴, PhD; Kenny De Meirleir ^{1, 3}, MD, PhD. High Prevalence of Mycoplasma infections among European Chronic Fatigue Syndrome patients: Examination of four Mycoplasma species in blood of Chronic Fatigue Syndrome patients. *FEMS Immunol Med Microbiol* 2002; 34:209-214
23. Buchwald D, Cheney PR, Peterson DL et al. A chronic illness characterized by fatigue, neurologic and immunologic disorders, and active human herpesvirus type 6 infection. *Ann Intern Med* 1992;116:103-113.
24. Zorenzenon M, Rukh G Botta GA et al. Active HHV-6 infection in chronic fatigue syndrome patients from Italy: New data. *J Chron Fatigue Syndr* 1996;2(4):3-12.
25. Knox KK, Brewer JH, and Carrigan DR. Persistent active human herpesvirus six (HHV-6) infections in patients with chronic fatigue syndrome. *J Chron Fatigue Syndrome* 1999;5:245-246.
26. Brewer JH, Know KK and Carrigan DR. Longitudinal study of chronic active human herpesvirus 6 (HHV-6) viremia in patients with chronic fatigue syndrome. Abstract. IDSA. 37th Annual Meeting. Nov. 18-21, 1999. Philadelphia, Pennsylvania.
27. Blatman H, Effective Treatment of Fibromyalgia and Myofascial Pain Syndrome: A Clinician's Perspective. *Journal of the American Academy of Pain Management*. April 2002.
28. Hotopf, Wessely S. The prognosis of chronic fatigue syndrome: a systematic review. *Q J Med*;90:223-33.
29. Maghnie M et al. Diagnosis of GH deficiency in the transition period: accuracy of insulin tolerance test and insulin-like growth factor-I measurement. *European Journal of Endocrinology*, Vol 152, Issue 4, 589-596
30. Farr C. Physiological and Biochemical Responses to Intravenous Hydrogen peroxide in man. *Journal of Advancement in Medicine* 1988;1:113-129.
31. 2p. Griep EN, Boersma JW, de Kloet ER. Altered Reactivity of the Hypothalamic-Pituitary-Adrenal Axis in the Primary Fibromyalgia Syndrome. *J Rheumatol* 1993;20:469-74.
32. Dockrell H et al. Killing of Blood-Stage Murine Malaria Parasites by Hydrogen Peroxide. *Infection and Immunity* 1983;39:456-459.
33. Cleare AJ, Blair D, Chambers S, Wessely S, Urinary Free Cortisol in Chronic Fatigue Syndrome *Am J Psychiatry* 158:641-643, April 2001
34. Cleare A et al. Hypothalamo-Pituitary-Adrenal Axis Dysfunction in Chronic Fatigue Syndrome, and the Effects of Low-Dose Hydrocortisone Therapy. *The Journal of Clinical Endocrinology & Metabolism* 2001. 86(8):3545-3554.

35. Cleare AJ et al. Low-dose hydrocortisone in chronic fatigue syndrome: a randomized crossover trial. *Lancet* 1999 Feb 6;353(9151):455-8
36. Jefferies W. Cortisol and Immunity. *Med Hyp* 1991;34:198-208.
37. Takeshita S et al. Intravenous immunoglobulin preparations promote apoptosis in lipopolysaccharide-stimulated neutrophils via an oxygen-dependent pathway in vitro. *APMIS* 2005;113:269-77.
38. WOLFF, Fernando H., NHUCH, Claudio, CADORE, Luciana P. et al. Low-dose adrenocorticotropin test in patients with the Acquired Immunodeficiency Syndrome. *Braz. j. infect. dis. Apr.* 2001, vol.5, no.2
39. Gaab J, Huster D, Peisen R, Engert V, Schad T, Schurmeyer TH, Ehlert U. Low-dose dexamethasone suppression test in chronic fatigue syndrome and health. *Psychosom Med.* 2002 Mar-Apr;64(2):311-8
40. Altemus M, Dale JK, Michelson D, Demitrack MA, Gold PW, Straus SE. Abnormalities in response to vasopressin infusion in chronic fatigue syndrome. *Psychoneuroendocrinology* 2001 Feb 1;26(2):175-188
41. Wentworth P Jr, McDunn JE, Wentworth AD, Takeuchi C, Nieva J, Jones T, Bautista C, Ruedi JM, Gutierrez A, Janda KD, Babor BM, Eschenmoser A, Lerner RA. Evidence for antibody-catalyzed ozone formation in bacterial killing and inflammation. *Science.* 2002 Dec 13;298(5601):2143-4.
42. Scott LV, Svec F, Dinan T. A preliminary study of dehydroepiandrosterone response to low-dose ACTH in chronic fatigue syndrome and in healthy subjects. *Psychiatry Res* 2000 Dec 4;97(1):21-28
43. Scott LV, Teh J, Reznick R, Martin A, Sohaib A, Dinan TG. Small adrenal glands in chronic fatigue syndrome: a preliminary computer tomography study. *Psychoneuroendocrinology* 1999 Oct;24(7):759-68
44. Heim C, Ehlert U, Hellhammer DH The potential role of hypocortisolism in the pathophysiology of stress-related bodily disorders. *Psychoneuroendocrinology.* 2000 Jan;25(1)
45. Scott LV, Medbak S, Dinan TG. Desmopressin augments pituitary-adrenal responsiveness to corticotropin-releasing hormone in subjects with chronic fatigue syndrome and in healthy volunteers. *Biol Psychiatry* 1999 Jun 1;45(11):1447-54.
46. De Becker P, De Meirleir K, Joos E, Campine I, Van Steenberge E, Smits J, Velkeniers B Dehydroepiandrosterone (DHEA) response to i.v. ACTH in patients with chronic fatigue syndrome. *Horm Metab Res* 1999 Jan;31(1):18-21.
47. Z Crofford L. The hypothalamic-pituitary-adrenal stress axis in fibromyalgia and chronic fatigue syndrome. *J Rheumatol* 1998;57 Suppl 2:67-71
48. Kuratsune H, Yamaguti K, Sawada M, Kodate S, Machii T, Kanakura Y, Kitani T. Dehydroepiandrosterone sulfate deficiency in chronic fatigue syndrome. *Int J Mol Med* 1998 Jan;1(1):143-6.
49. Scott LV, Medbak S, Dinan TG The low dose ACTH test in chronic fatigue syndrome and in health. *Clin Endocrinol (Oxf)* 1998 Jun;48(6):733-7.
50. Scott LV, Medbak S, Dinan TG. Blunted adrenocorticotropin and cortisol responses to corticotropin-releasing hormone stimulation in chronic fatigue syndrome. *Acta Psychiatr Scand* 1998 Jun;97(6):450-457
51. Strickland P, Morriss R, Wearden A, Deakin B A comparison of salivary cortisol in chronic fatigue syndrome, community depression and healthy controls. *J Affect Disord* 1998 Jan;47(1-3):191-194

52. Strickland P, Morriss R, Wearden A, Deakin B. A comparison of salivary cortisol in chronic fatigue syndrome, community depression and healthy controls. *J Affect Disord* 1998 Jan;47(1-3):191-194
53. Jefferies W. Mild adrenocortical deficiency, chronic allergies, autoimmune disorders and the chronic fatigue syndrome: a continuation of the cortisone story, *Med Hypotheses*, 1994, Issue: 3, Volume: 42, Page: 183-9, ISSN: 0306-9877
54. Cleare AJ; Bearn J; Allain T; McGregor A; Wessely S; Murray RM; O'Keane V. Contrasting neuroendocrine responses in depression and chronic fatigue syndrome, *J Affect Disord*, 1995 Aug 18, Issue: 4 Volume: 34 Page: 283-9
55. Moutschen M; Triffaux JM; Demonty J; Legros JJ; Lefèbvre PJ; . Pathogenic tracks in fatigue syndromes *Acta Clin Belg*, 1994, Issue: 6 Volume: 49 Pagination: 274-89 ISSN: 0001-5512
56. Carruthers et al. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Clinical Working Case Definition, Diagnostic and Treatment Protocols. *Journal of Chronic Fatigue Syndrome*. Vol 11(1) 2003.
57. Demitrack MA, Crofford LJ. Evidence for and pathophysiologic implications of hypothalamic-pituitary-adrenal axis dysregulation in fibromyalgia and chronic fatigue syndrome. *Ann N Y Acad Sci* 1998 May 1;840:684-697.
58. Tordjman K., Jaffe A., Grazas N. et al. The role of the low dose (1 mg) adrenocorticotropin test in the evaluation of patients with pituitary diseases. *J Clin Endocrinol Metab* 1995; 80:1301-5.
59. Dickstein G., Schechner C., Nicholson W.E., et al. Adrenocorticotropin stimulation test: effects of basal cortisol level, time of the day, and suggested new sensitive low dose test. *J Clin Endocrinol Metab* 1991;72:773-8.
60. Crowley S., Hindmarsh P.C., Honour J.W., Brook C.G.D. Reproducibility of the cortisol response to stimulation with a low dose of ACTH (1-24): the effect of basal cortisol levels and comparison of low dose with high dose secretory dynamics. *J Endocrinol* 1993;136:167-72.
61. Baraia-Etxaburu Artetxe J., Astigarraga Aguirre B., Elorza Olabegova R., et al. [Primary adrenal failure and AIDS: report of 11 cases and review of the literature]. *Rev Clin Esp* 1998;198:74-9.
62. Zarkovic M., Ciric J., Stojanovic M., et al. Optimizing the diagnostic criteria for standard (250-mg) and low dose (1-mg) adrenocorticotropin tests in the assessment of adrenal function. *J Clin Endocrinol Metab* 1999;84:3170-3.
63. Abdu T.A., Elhadd T.A., Neary R., Clayton R.N. Comparison of the low dose short synacthen test (1 mg), the conventional dose short synacthen test (250 mg), and the insulin tolerance test for assessment of the hypothalamo-pituitary-adrenal axis in patients with pituitary disease. *J Clin Endocrinol Metab* 1999;84:838-43.
64. Jefferies W. Mild Adrenocortical Deficiency, Chronic Allergies, Autoimmune disorders and Chronic Fatigue syndrome: A Continuation of the Cortisone Story. *Medical Hypotheses* 1994;42, 183-189
65. Jefferies W. Cortisol and Immunity. *Medical Hypotheses* 1991;34:198-208
66. Grayson J et al. Immunoglobulin production induced in vitro by glucocorticoid hormones: T-cell dependent stimulation of immunoglobulin production without B cell proliferation in cultures of human peripheral blood lymphocytes. *J clin Invest* 68:1539,1981.
67. Chappel MR. Infectious mononucleosis. *Southwest Med* 43:253,1962.

68. Bender CE. The value of corticosteroids in the treatment of infectious mononucleosis. *JAMA* 199;529, 1967
69. Manji RJ et al. Depression of cell-mediated immunity during acute infectious mononucleosis. *N Engl J Med* 291:1149, 1974
70. JEROEN T.J. VISSERa,b,d, E. RONALD DE KLOETb and LEX NAGELKERKEN. Altered Glucocorticoid Regulation of the Immune Response in the Chronic Fatigue Syndrome. *Annals of the New York Academy of Sciences* 917:868-875 (2000) © 2000
71. McKenzie et al. Low-Dose Hydrocortisone for Chronic Fatigue Syndrome. 281 No. 20, May 26, *JAMA*,1999 Vol. 281 No. 20, May 26, 1999
72. Teitelbaum et al. To the Editor re: McKenzie et al. Low-Dose Hydrocortisone for Chronic Fatigue Syndrome. 281 No. 20, May 26, *JAMA*,1999 Vol. 281 No. 20, May 26, 1999. *JAMA* May 26, 1999 (281)20:1888.
73. Bou-holaigah I et al. The Relationship Between Neurally Medicated Hypotension and the Chronic Fatigue Syndrome. *JAMA* 1995;274;12:961-967
74. Naschitz JE et al. The head-up tilt test with haemodynamic instability score in diagnosing chronic fatigue syndrome. *QJ Med* 2003;96:133-142
75. American Association of Clinical Endocrinologists. Member alert: Subclinical Hypothyroidism. May 12, 2004. 14:06:55
76. Hak A et al. Subclinical Hypothyroidism is an Independent Risk Factor for Atherosclerosis and Myocardial Infarction in Elderly Women: the Rotterdam Study. *Annals of Internal Medicine* 15 February 2000;4:270-8.
77. Principles and Practice of Endocrinology and Metabolism 3rd ed. Kenneth Becker, Editor. Lippincott Williams & Wilkins. 2001.
78. McDermott M Ridgway C. CLINICAL PERSPECTIVE: Subclinical Hypothyroidism Is Mild Thyroid Failure and Should be Treated. *The Journal of Clinical Endocrinology & Metabolism* 86(10):4585–4590
79. Monzani F, Del Guerra P, Caraccio N, Pruneti CA, Pucci E, Luisi M, et al. 1993 Subclinical hypothyroidism: neurobehavioral features and beneficial effect of l-thyroxine treatment. *Clin Invest* 71:367–371
80. Tappy L, Randin JP, Schwed P, Wertheimer J, Lemarchand-Beraud T 1987 Prevalence of thyroid disorders in psychogeriatric inpatients. A possible relationship of hypothyroidism with neurotic depression but not dementia. *J Am Geriatr Soc* 35:526–531
81. Joffe RT, Levitt AJ 1992 Major depression and subclinical (grade 2) hypothyroidism. *Psychoneuroendocrinology* 17:215–221
82. Haggerty Jr JJ, Stern RA, Mason GA, Beckwith J, Morey CE, Prange Jr AJ 1993 Subclinical hypothyroidism: A modifiable risk factor for depression? *Am J Psychiatry* 150:508–510
83. Manciet G, Dartigues JF, Decamps A, et al. 1995 The PAQUID survey and correlates of subclinical hypothyroidism in elderly community residents in the southwest of France. *Age Aging* 24:235–241
84. Baldini IM, Vita A, Maura MC, et al. 1997 Psychological and cognitive features in subclinical hypothyroidism. *Prog Neuropsychopharmacol Biol Psychiatry* 21:925–935

85. Ganguli M, Burmeister LA, Seaberg EC, Belle S, DeKosky ST 1996 Association between dementia and elevated TSH: a community-based study. *Biol Psychiatry* 40:714–725
86. Monzani F, Caraccio N, Siciliano G, Manca L, Murri L, Ferrannini E 1997 Clinical and biochemical features of muscle dysfunction in subclinical hypothyroidism. *J Clin Endocrinol Metab* 82:3315–3318
87. Monzani F, Caraccio N, Del Guerra P, Casolaro A, Ferrannini E 1999 Neuromuscular symptoms and dysfunction in subclinical hypothyroid patients: beneficial effect of L-T4 replacement therapy. *Clin Endocrinol* 51:237–242
88. Misiunas A, Ravera HN, Faraj G, Faure E 1995 Peripheral neuropathy in subclinical hypothyroidism. *Thyroid* 5:283–286
89. Goulis DG, Tsimpiris N, Delaroudis S, et al. 1998 Stapedial reflex: A biological index found to be abnormal in clinical and subclinical hypothyroidism. *Thyroid* 8:583–587
90. Beyer IW, Karmali R, DeMeester-Mirkine N, Cogan E, Fuss MJ 1998 Serum creatine kinase levels in overt and subclinical hypothyroidism. *Thyroid* 8:1029–1031
91. Haddow JE, Palomaki GE, Allan WC, et al. 1999 Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. *N Engl J Med* 341:549–555
92. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC 2000 The Colorado thyroid disease prevalence study. *Arch Intern Med* 160:526–534
93. Ridgway EC, Cooper DS, Walker H, Rodbard D, Maloof F 1981 Peripheral responses to thyroid hormone before and after L-thyroxine therapy in patients with subclinical hypothyroidism. *J Clin Endocrinol Metab* 53:1238–1242
94. Cooper DS, Halpern R, Wood LC, Levin AA, Ridgway EC 1984 L-thyroxine therapy in subclinical hypothyroidism. *Ann Intern Med* 101:18–24
95. Nystrom E, Caidahl K, Fager G, Wikkelso C, Lundberg P-A, Lindstedt G 1988 A double-blind cross-over 12-month study of L-thyroxine treatment of women with 'subclinical' hypothyroidism. *Clin Endocrinol* 29:63–76
96. Bell GM, Todd WT, Forfar JC, et al. 1985 End-organ responses to thyroxine therapy in subclinical hypothyroidism. *Clin Endocrinol (Oxf)* 22:83–89
97. Forfar JC, Wathen CG, Todd WT, et al. 1985 Left ventricular performance in subclinical hypothyroidism. *QJ Med* 57:857–865
98. Foldes J, Istvanfy M, Halmagyi M, Varadi A, Gara A, Partos O 1987 Hypothyroidism and the heart. Examination of left ventricular function in subclinical hypothyroidism. *Acta Med Hung* 44:337–347
99. Kahaly GJ 2000 Cardiovascular and atherogenic aspects of subclinical hypothyroidism. *Thyroid* 10:665–679
100. Arem R, Rokey R, Kiefe C, Escalante DA, Rodriguez A 1996 Cardiac systolic and diastolic function at rest and exercise in subclinical hypothyroidism: Effect of thyroid hormone therapy. *Thyroid* 6:397–402
101. Monzani F, Di Bello V, Caraccio N, et al. 2001 Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism: a double blind,
102. Tanis BC, Westendorp RGJ, Smelt AHM 1996 Effect of thyroid substitution on hypercholesterolaemia in patients with subclinical hypothyroidism: a re-analysis of intervention studies. *Clin Endocrinol* 44:643–649

103. Danese MD, Ladenson PW, Meinert CL, Powe NR 2000 Effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. *J Clin Endocrinol Metab* 85:2993–3001
104. M P J Vanderpump, senior registrar, a J A O Ahlquist, consultant physician, b J A Franklyn, Consensus statement for good practice and audit measures in the management of hypothyroidism and hyperthyroidism. *BMJ* 1996;313:539-544 (31 August).
105. P. A. Singer, D. S. Cooper, E. G. Levy, P. W. Ladenson, L. E. Braverman, G. Daniels, F. S. Greenspan, I. R. McDougall and T. F. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. Vol. 273 No. 10, March 8, 1995
106. Michalopoulou G, Alevizaki M, Pipingos G, et al. 1998 High serum cholesterol levels in persons with 'high normal' TSH levels: should one extend the definition of subclinical hypothyroidism. *Eur J Endocrinol* 138:141–145
107. Bindels AJ, Westendorp RG, Frolich M, Seidell JC, Blokstra A, Smelt AH 1999 The prevalence of subclinical hypothyroidism at different total plasma cholesterol levels in middle aged men and women: a need for case-finding? *Clin Endocrinol* 50:217–220
108. Bakker SJL, Ter Matten JC, Popp-Snijders C, Slaets JPJ, Heine RJ, Gans ROB 2001 The relationship between thyrotropin and low density lipoprotein cholesterol is modified by insulin sensitivity in healthy euthyroid subjects. *J Clin Endocrinol Metab* 86:1206–1211.
109. Pasternak RC, Smith SC Jr, Biarey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. *J Am Coll Cardiol* 2002; 40:567-572.
110. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. *JAMA* 2003; 289:1681-1690.
111. Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. *Drug Saf* 2000; 6:441-447.
112. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. *Ann Pharmacother* 2001; 35:1096-1107.
113. Bo Isomaa, MD1, Peter Almgren, MSC2, Tiinamajja Tuomi, MD3, Björn Forsén, MD4, Kaj Lahti, MD5, Michael Nissén, MD6, Marja-Riitta Taskinen, MD3 and Leif Groop, MD7 Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome *Diabetes Care* 24:683-689, 2001
114. William I. Sivitz, MD. Symposium on Insulin Resistance: Understanding insulin resistance: What are the clinical implications? Vol 116 / NO 1 / July 2004 / Postgraduate Medicine
115. Fasting Insulin Levels as a Measure of Insulin Resistance in American Blacks R, Blanche M, Yolette S, Pedra-Nobre M, Bigg D, *The Journal of Applied Research* • Vol. 4, No. 1, 2004.
116. A Joint Initiative of the Royal College of pathologists of Ausrial. Commonsense pathology: Insulin Resistance. Unit 6, Dec 2002
117. Patricia Vuguin, Paul Saenger and Joan Dimartino-Nardi. *The Journal of Clinical. Fasting Glucose Insulin Ratio: A Useful Measure of Insulin Resistance in Girls with Premature Adrenarche. Endocrinology & Metabolism* Vol. 86, No. 10 4618-4621.
118. T. Bitó, I. Földesi, T. Nyári and A. Pál. Prediction of gestational diabetes mellitus in a high-risk group by insulin measurement in early pregnancy. *Diabetic Medicine* Volume 22 Issue 10 Page 1434 - October 2005

119. Rose SR; Lustig RH; Pitukcheewanont P; Broome DC; Burghen GA; Li H; Hudson MM; Kun LE. Diagnosis of hidden central hypothyroidism in survivors of childhood cancer. *J Clin Endocrinol Metab* 1999 Dec;84(12):4472-9
120. Wikland B, Lowhagen T, Sandberg PO. Fine needle aspiration cytology of the thyroid in chronic fatigue. *Lancet* 2001;357:956-57.
121. Garrison RL, Breeding PC. A metabolic basis for fibromyalgia and its related disorders: the possible role of resistance to thyroid hormone. *Medical Hypotheses* (2003)61(2),182-189.
122. Cullum ME et al. Mutations in the c-erbB1 gene: do they underlie euthyroid fibromyalgia. *Medical Hypotheses* (1997)48. 125-135
123. Lowe J, Garrison R, Reichman A, MD, Yellin J, Thompson BA, Kaufman D. Effectiveness and safety of T3 (triiodothyronine) therapy for euthyroid fibromyalgia: a double-blind placebo-controlled response-driven crossover study.: *Clinical Bulletin of Myofascial Therapy*, 2(2/3):31-58, 1997.
124. Lowe JC ,Reichman AJ, Yellin J. The process of change during T3 treatment for euthyroid fibromyalgia: a double-blind placebo-controlled crossover study.: *Clinical Bulletin of Myofascial Therapy*, 2(2/3):91-124, 1997.
125. Lowe JC ,Reichman AJ, Garrison R, Yellin J.. Triiodothyronine (T3) treatment of euthyroid fibromyalgia: a small-n replication of a double-blind placebo-controlled crossover study. *Clinical Bulletin of Myofascial Therapy*, 2(4):71-88, 1997.
126. Yellin BA, Reichman AJ, Lowe JC ,The process of Change During T3 Treatment for Euthyroid Fibromyalgia: A Double-Blind Placebo-Controlled Crossover Study. *The Metabolic Treatment of Fibromyalgia*. McDowell Publishing 2000.
127. Adler, Gail K. Hormonal changes and fibromyalgia. *Current Opinion in Endocrinology & Diabetes*. 6(1):55, February 1999.
128. YC Patel and HG Burger Serum thyrotropin (TSH) in pituitary and-or hypothalamic hypothyroidism: normal or elevated basal levels and paradoxical responses to thyrotropin-releasing hormone *J Clin Endocrinol Metab* 1973 37: 190-196.
129. G Faglia G et al. Plasma thyrotropin response to thyrotropin-releasing hormone in patients with pituitary and hypothalamic disorders *J Clin Endocrinol Metab* 1973 37: 595-601.
130. Hall R. The immununoassay of thyroid-stimulating hormone and its clinical application. *Clin Endocrinol (Oxf)*1972; 1:115-25.
131. Thyrotropin-releasing hormone in patients with pituitary and hypothalamic disorders. *J Clin Endocrinol Metab* 1973; 37:595-601.
132. Mitsuma T, Shenkman L, Suphavi A, Hollander CS. Hypothalamic hypothyroidism: diminished thyroidal response to thyrotropin-releasing hormone. *Am J Med Sci* 1973. 265:315-8.
133. Krieger DT. Glandular and organ deficiency associated with secretion of biologically inactive pituitary peptides. *J Clin Endocrinol Me.lab* 1974; 38:964-75.
134. Illig R, Kmwezyriska H, Tonesuni 'P, Pmdr A. Elevated plasma TSH and hypothyroidism in children with hypothalamic hypopituitarism. *J Clin Endocrinol Metab* 1975; 41:722-8.
135. Faglia G, Ferrari C, Paracchi A, Spada A, Beck-Peccoz P. Triiodothyronine response to thyrotrophin-releasing hormone in patients with hypothalamic-pituitary disorders. *Clin Endocrinol (Oxf)* 1975: 4:585-90.
136. Joshi LR et al. 1983. natural occurring forms of thyrotropin with low bioactivity and altered

- carbohydrate metabolism act as competitive antagonist. *Endocrinology* 113:2145-2145-2154
137. Weintraub BD, Stannard BS et al. Glycosylation and posttranslational processing of thyroid-stimulation hormone; clinical implications. *Rec Prog Horm Res* 41:577-606
 138. Hartree AS, Renwick AGC 1992 Molecular structures of glycoprotein hormones... *Biochem J* 287:665-679
 139. Szkudlinski MW, Thotakura NR, Bucci I, et al. 1993 Purification and characterization of recombinant human thyrotropin (TSH-1) isoforms produced by Chinese hamster ovary cells: the role of sialylation and sulfation in TSH. *Endocrinology*, Vol 133, 1490-1503,
 140. Miura, Perkel VS, Papenberg G, Johnson MJ, Magner JA. Concanavalin-A, lentil, and ricin lectin affinity binding characteristics of human thyrotropin: differences in the sialylation of thyrotropin in sera of euthyroid, primary, and central hypothyroid patients. *J Clin Endocrinol Metab* 1989 69: 985-995.
 141. Beck-Peccoz P, Persani L. 1994 Variable biological activity of thyroid-stimulating hormone. *Eur J Endocrinol*. 131:331-340.
 142. Persani L. 1998 Hypothalamic thyrotropin-releasing hormone and thyrotropin biological activity. *Thyroid*. 8:941-946.
 143. Faglia G, Bitensky L, Pinchera A, et al. 1979 Thyrotropin secretion in patients with central hypothyroidism: evidence for reduced biological activity of immunoreactive thyrotropin. *J Clin Endocrinol Metab*. 48:989 -998
 144. Samuel A. McLean,¹ David A. Williams,¹ Richard E. Harris,¹ Willem J. Kop,² Kimberly H. Groner,¹ Kirsten Ambrose,¹ Angela K. Lyden,¹ Richard H. Gracely,¹ Leslie J. Crofford,³ Michael E. Geisser,¹ Ananda Sen,¹ Pinaki Biswas,¹ and Daniel J. Clauw¹. Momentary Relationship Between Cortisol Secretion and Symptoms in Patients With Fibromyalgia. *Arthritis & Rheumatism* Vol. 52, No. 11, November 2005, pp 3660–3669
 145. Cottage, F. Correspondence. *The Lancet* 1999 (353) May 8;1619.
 146. Bou-Holaigah et al. the relationship between neurally mediated hypotension and the chronic fatigue syndrome. *JAMA* 1995;274:961-7.
 147. Bashetti R. hydrocortisone and chronic Fatigue Syndrome. *Lancet* 1999;353:1618.
 148. Riccardo Baschetti, M.D. Investigations of Hydrocortisone and Fludrocortisone in the Treatment of Chronic Fatigue Syndrome *The Journal of Clinical Endocrinology & Metabolism* Vol. 84, No. 6 2263-2264
 149. Elisabetta Ferretti, Luca Persani, Marie-Lise Jaffrain-Rea, Salvatore Giambona, Guido Tamburrano and Paolo Beck-Peccoz. Evaluation of the Adequacy of Levothyroxine Replacement Therapy in Patients with Central Hypothyroidism¹. *The Journal of Clinical Endocrinology & Metabolism* Vol. 84, No. 3 924-929.
 150. Henryk Zulewski, Beat Müller, Pascale Exer, André R. Miserez and Jean-Jacques Staub Estimation of Tissue Hypothyroidism by a New Clinical Score: Evaluation of Patients with Various Grades of Hypothyroidism and Controls¹ *The Journal of Clinical Endocrinology & Metabolism* Vol. 82, No. 3 771-776
 151. Fraser WD et al. Are biochemical tests of thyroid function of any value in monitoring patients receiving thyroxine replacement?. *BRITISH MEDICAL JOURNAL* 1986. VOLUME 293, 27 SEPTEMBER
 152. Henryk Zulewski, Beat Müller, Pascale Exer, André R. Miserez and Jean-Jacques Staub Estimation of Tissue Hypothyroidism by a New Clinical Score: Evaluation of Patients with Various Grades of Hypothyroidism and Controls¹ *The Journal of Clinical Endocrinology & Metabolism* Vol. 82, No. 3 771-776

153. Meier C, Trittbach P, Guglielmetti M, Staub J-J, Müller B. Serum thyroid stimulating hormone in assessment of severity of tissue hypothyroidism in patients with overt primary thyroid failure: cross sectional survey. *Brit Med J* 2003;326:311-312 (8 February)
154. Yellin BA, Reichman AJ, Lowe JC. The process of Change During T3 Treatment for Euthyroid Fibromyalgia: A Double-Blind Placebo-Controlled Crossover Study. *The Metabolic Treatment of Fibromyalgia*. McDowell Publishing 2000.
155. Escobar-Morreale et al. Replacement therapy for hypothyroidism with thyroxine alone does not ensure euthyroidism in all tissues, as studied in thyroidectomized rats, *J Clin Invest*, 1995
156. Georg Hennemann, Roelof Docter, Edith C. H. Friesema, Marion de Jong, Eric P. Krenning and Theo J. Visser. Plasma Membrane Transport of Thyroid Hormones and Its Role in Thyroid Hormone Metabolism and Bioavailability. *Endocrine Reviews* 22 (4): 451-476
157. Boeleart K et al. Starling Review: Thyroid Hormone in health and disease. *Journal of Endocrinology* 2005 May 23:1-47.
158. Friesema EC, Ganguly S, Abdalla A, Manning Fox JE, Halestrap AP & Visser TJ 2003 Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter. *Journal of Biological Chemistry* 278 40128-40135.
159. Friesema EC, Grueters A, Biebermann H, Krude H, von Moers A, Reeser M, Barrett TG, Mancilla EE, Svensson J, Kester MH, Kuiper GG, Balkasmi S, Uitterlinden AG, Koehrle J, Rodien P, Halestrap AP & Visser TJ 2004 Association between mutations in a thyroid hormone transporter and severe X-linked psychomotor retardation. *Lancet* 364 1435-1437.
160. SADOVSKY R. Subclinical Thyroid Dysfunction Affects the Heart. *American Family Physician*. April 1, 2003.
161. Larsen P et al. Relationship between circulation and intracellular thyroid hormones: Physiological and clinical implications. *Endocrine Reviews* 1981;2:87-102.
162. Werner & Ingbar's *The Thyroid: A Fundamental and Clinical Text*. Eighth Ed. Braverman L, Utiger R. Lippincott Williams & Wilkins.
163. Bernadette Biondi, Emiliano Antonio Palmieri, Serafino Fazio, Carmela Cosco, Maria Nocera, Luigi Saccà, Sebastiano Filetti, Gaetano Lombardi and Francesco Perticone. Endogenous Subclinical Hyperthyroidism Affects Quality of Life and Cardiac Morphology and Function in Young and Middle-Aged Patients. *The Journal of Clinical Endocrinology & Metabolism* Vol. 85, No. 12 4701-4705
164. J Faber, N Wiinberg¹, S Schifter² and J Mehlsen. Haemodynamic changes following treatment of subclinical and overt hyperthyroidism. *European Journal of Endocrinology* (2001) 145 13-396.
165. *The Metabolic treatment of fibromyalgia*. Lowe J. 2000. McDowell Publishing Company
166. Dillman W, Ladenson P, Daniels G. Thyroid Disease and the Heart. *The Endocrine Society 85th Annual Meeting* 2003.
167. Circulating Blood Volume in Chronic Fatigue Syndrome Streeten D, Be11 D. *Journal of Chronic Fatigue Syndrome*, Vol. 4(1) 1998
168. *Principles and Practice of Endocrinology and Metabolism* 3rd ed. Becker K. 2001. Lippincott Williams & Wilkins.
169. Lenfant C, *New England Journal of Medicine*. Clinical Research to Clinical Practice-Lost in

Translation 2003;349:868-874.

170. William Shankle, M.D. Key Note Presentation. International Conference on the Integrative Medical approach to the Prevention of Alzheimer's Disease. Oct 11, 2003.
171. Phillip Pizzo, MD. Stanford Medical Magazine. Stanford University Scholl of Medicine.
172. Begley S. Too Many Patients Never Reap the Benefits of Great Research. Wall Street Journal September 26, 2003.
173. Science Know Best. Daily Policy Digest. National Center for Policy Analysis. Sept 26, 2003.
174. Rosenfeld et al. Diagnostic Controversy: The diagnosis of childhood growth Hormone deficiency revisited. Journal of Endocrinology and Metabolism.
175. Moore DC, Ruvalcaba RH, Smith EK, Kelley VC. Plasma somatomedin-C as a screening test for growth hormone deficiency in children and adolescents. Horm Res. 1982;16(1):49-55.
176. Cacciari E, Cicognani A, Pirazzoli P, Tassoni P, Salardi S, Capelli M, Zucchini S, Natali G, Righetti F, Ballardini D. Differences in somatomedin-C between short-normal subjects and those of normal height. J Pediatr. 1985 Jun;106(6):891-4.
177. Bennett R. Growth Hormone in Musculoskeletal Pain States. Current Pain and Headache Reports 2005, 9:331-338
178. Jo Nijs J et al. High prevalence of Mycoplasma infections among European chronic fatigue syndrome patients. Examination of four Mycoplasma species in blood of chronic fatigue syndrome patients. . Volume 34, Issue 3 , 15 November 2002, Pages 209-214.
179. Gerhard K. M. Endresen. Mycoplasma blood infection in chronic fatigue and fibromyalgia syndromes. Rheumatology International Issue: Volume 23, Number 5 September 2003: 211 – 215
180. Nasralla M, Haier J, Nicolson GL. Multiple mycoplasmal infections detected in blood of patients with chronic fatigue syndrome and/or fibromyalgia syndrome. Eur J Clin Microbiol Infect Dis 1999 Dec;18(12):859-65.
181. Nicolson GL, Gan R, Haier J. Multiple co-infections (Mycoplasma, Chlamydia, human herpes virus-6) in blood of chronic fatigue syndrome patients: association with signs and symptoms. APMIS. 2003 May; 111(5): 557-66.
182. Vojdani A, Choppa PC, Tagle C, Andrin R, Samimi B, Lapp CW. Detection of Mycoplasma genus and Mycoplasma fermentans by PCR in patients with Chronic Fatigue Syndrome. FEMS Immunol Med Microbiol 1998 Dec;22(4):355-65
183. Choppa PC, Vojdani A, Tagle C, Andrin R, Magtoto L. Multiplex PCR for the detection of Mycoplasma fermentans, M. hominis and M. penetrans in cell cultures and blood samples of patients with chronic fatigue syndrome. Mol Cell Probes 1998 Oct;12(5):301-8
184. Marwan Nasralla, Ph.D., Joerg Haier, M.D., Ph.D. and Garth L. Nicolson, Ph.D. Mycoplasmal Infections in Blood from Patients with Chronic Fatigue Syndrome, International CFS Conference, Sydney, Australia, 1998.
185. Vojdani, Aristo, and Al Robert Franco. Multiplex PCRF for the Detection of Mycoplasma fermentans, M. hominis, and M. penetrans in Patients with Chronic Fatigue Syndrome, Fibromyalgia, Rheumatoid Arthritis, and Gulf War Syndrome. Journal of Chronic Fatigue Syndrome Vol. T, No. ¾, 1999, pp. 187-197;
186. Vojdani, A, Franco A. Chronic Fatigue Syndrome: Advance in Epidemiologic, Clinical, and Basic Science Research. 1999, pp. 187-197. The Haworth Press, Inc., 1999

187. Nicolson G, Nicolson N. diagnosis and treatment of Mycoplamlal Infections in Persian Gulf War Illness-CFIDS Patients. *International Journal of Occupational Medicine, Immunology and Toxicology* 1996;5:69-78.
188. Nasralla M et al. The Pathogenesis and Treatment of Mycoplasmal Infections. *Antimicrobics and Infectious Disease Newsletter* 1999;17(!);81-88.
189. C. Hoffman, D. Rice and H. Y. Sung. Persons with chronic conditions. Their prevalence and costs. *JAMA*. Vol. 276 No. 18, November 13, 1996.
190. Nicolson G, Nasralla M, Franco R, DeMeirleir K et al. Role of Mycoplamsal Infections in Fatigue Illness: Chronic Fatigue and Fibromyalgia Syndromes, Gulf War Illness and Rheumatoid Arthritis. *Journal of Chronic Fatigue Syndrome* 2000;6(3/4):23-39.
191. Garth L. Nicolson, Marwan Nasralla, Joerg Haier and Nancy L. Nicolson Diagnosis and Treatment of Chronic Mycoplasmal Infections in Fibromyalgia and Chronic Fatigue Syndromes: Relationship to Gulf War Illness. *Biomed. Therapy* 1998; 16: 266-271
192. Baseman JB, Tully JG. Mycoplasmas: Sophisticated, reemerging, and burdened by their Notoriety. *Emerg Infect Dis* 1997 (3): 21-32.
193. Lo S-C, Dawson MS, Newton PB III. Association of the virus-like infectious agent originally reported in patients with AIDS with acute fatal disease in previously healthy non-AIDS patients. *Am J Trop Med Hyg* 1989 (40): 399-409.
194. Lo SC, Wear DJ, Shih WK, Wang RYH, Newton PB, Rodriguez JF. Fatal systemic infections of non-human primates by *Mycoplasma fermentans* (incognitus strain). *Clin Infect Dis* 1993 (17) (Suppl 1): S283-288.
195. Lo SC, Buchholz CL, Wear DJ, Hohm RC, Marty AM. Histopathology and doxycycline treatment in a previously healthy non-AIDS patient systemically infected by *Mycoplasma fermentans* (incognitus strain). *Mod Pathol* 1991 (6): 750-754.
196. Marwan Y. Nasralla, Jörg Haier, Nancy L. Nicolson Garth L. Nicolson. Examination of Mycoplasmas in Blood of 565 Chronic Illness Patietns by Polymerase Chain Reaction.. *International Journal Medicine Biology Environment* 2000; 28(1):15-23.
197. Ablashi DV, Zompetta C, Lease C, Josephs SF, Balachandran N, Komaroff AL, Krueger GRF, Henry B, Luka J and Salahuddin SZ. Human herpesvirus-6 (HHV-6) and chronic fatigue syndrome (CFS). *Canada Disease Weekly Report* 1991; 175E:33-40.
198. Zorenzenon M, Rukh G Botta GA et al. Active HHV-6 infection in chronic fatigue syndrome patients from Italy: New data. *J Chron Fatigue Syndr* 1996;2(4):3-12.
199. Knox KK, Brewer JH, and Carrigan DR. Persistent active human herpesvirus six (HHV-6) infections in patients with chronic fatigue syndrome. *J Chron Fatigue Syndr* 1999;5:245-246.
200. Brewer JH, Know KK and Carrigan DR. Longitudinal study of chronic active human herpesvirus 6 (HHV-6) viremia in patients with chronic fatigue syndrome. Abstract. IDSA. 37th Annual Meeting. Nov. 18-21, 1999. Philadelphia, Pennsylvania.
201. Banks TA and Rouse BT. Herpesviruses – Immune escape artists? *Clin Infect Dis* 1992;14:933-941.
202. Brewer JH, Knox KK, and Carrigan DR. Severe dysfunction of natural killer (NK) cells associated with chronic active human herpesvirus-6 (HHV-6) viremia in patients with chronic fatigue syndrome. Abstract. IDSA. 37th Annual Meeting. Nov. 18-21, 1999. Philadelphia, Pennsylvania.
203. J K S Chia. The role of enterovirus in chronic fatigue syndrome *Journal of Clinical Pathology* 2005; 58:1126-1132; doi:10.1136/jcp.2004.020255 2005

204. Brewer J. TREATMENT OF ACTIVE HHV-6 INFECTION WITH HHV-6 SPECIFIC TRANSFER FACTOR IN PATIENTS WITH CHRONIC FATIGUE SYNDROME American Association for AACFS Chronic Fatigue Syndrome. Spring 2004.
205. Viza D, Vich JM, Phillips J et al. Orally administered specific transfer factor for the treatment of herpesvirus infections. *Lymphok Res* 1985;4:27-30.
206. Fudenberg H and Pizza G. Transfer factor 1993: New frontiers. *Progress in Drug Res* 1994;42:309-400.
207. Lang I, Nekam H, Gergely P et al. Effect of in vivo and in vitro treatment with dialyzable leukocyte extracts on human natural killer cell activity. *Clin Immunol and Immunopathol* 1982;25:139-144.
208. Wilson GB and Paddock GV. Process of obtaining transfer factor from colostrum; transfer factor so obtained and use thereof. U.S. Patent 4,816,563 (1989).
209. Buchwald D. et al. A Chronic Illness Characterized by Fatigue, Neurological and Immunological Disorders, and Active Human Herpesvirus Type 6 Infection published in the *Annals of Internal Medicine* 1992;116:103-113.
210. Walsh JP, Bremner AP, Bulsara MK, O'Leary P, Leedman PJ, Feddema P, Michelangeli V. Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. *Arch Intern Med.* 2005 Nov 28;165(21):2467-72.
211. Wagner et al. Chronic Fatigue Syndrome: A critical Evaluation of Testing for Active Human Herpesvirus-6 Infection. Review of Data of 107 cases. *Jornal of Chronic Fatigue Syndrome*;2(4) 1996.
212. 15 Krueger GRF, Ablashi DV and Gallo RC: Persistent herpesvirus infections . Current techniques in diagnosis. *J Virol Methods* 21 : 1- 326,1988 .
213. Dylewski J, Chou S, Merigan TC. Absence of detectable IgM antibody during cytomegalovirus disease in patients with AIDS. *N Engl J Med* 1985; 309: 493.
214. Krueger GRF, Klueppelberg U, Hoffmann A, Ablashi DV. Clinical correlates of infection with human herpesvirus-6. *In Vivo* 1994; 8:457-86.
215. Lerner AM, Beqaj SH, and Deeter RG et al. A six-month trial of valacyclovir in the Epstein-Barr virus subset of chronic fatigue syndrome: improvement in left ventricular function. *Drugs of Today.* 2002;38:549-561.
216. Lerner AM, Zervos M and Dworkin HJ et al. New cardiomyopathy: A pilot study of intravenous ganciclovir in a subset of the chronic fatigue syndrome. *Infectious Diseases In Clinical Practice* 1997;6:110-117.
217. Lerner AM, Zervos M and Chang CH et al. A small, randomized, placebo-controlled trial of the use of antiviral therapy for patients with chronic fatigue syndrome. *Clinical Infectious Diseases.* 2001;32:1657-58.
218. See DM, Tilles JG. *Immunol Invest.* alpha-Interferon treatment of patients with chronic fatigue syndrome. 1996 Jan-Mar;25(1-2):153-64.
219. Brook MG, Bannister BA, Weir WR. Interferon-alpha therapy for patients with chronic fatigue syndrome. *J Infect Dis.* 1993 Sep;168(3):791-2.
220. J K S Chia. The role of enterovirus in chronic fatigue syndrome. *J. of clin Path* 2005;March 14:1126-1132.

221. Thomas M, Smith A. Primary healthcare provision and Chronic Fatigue Syndrome: a survey of patients' and General Practitioners' beliefs. *BMC Family Practice* 2005, 6:49 doi:10.1186/1471-2296-6-49.
222. Jo Bowen^a, Derek Pheby^b, Andre Charlett^c and Cliodna McNulty. Chronic Fatigue Syndrome: a survey of GPs' attitudes and knowledge. *Family Practice* 2005 22(4):389-393;
223. Oliver, T. H., et al., Influenzal pneumonia: the intravenous injection of hydrogen peroxide, *Lancet* 1:432-433 (1920)).
224. Green HN, Westrop JW. Hydrogen peroxide and tumor therapy. *Nature* 1958;181:128-9
225. Mallams JT, Finney JW, Balla GA. The use of hydrogen peroxide as a source of oxygen in a regional intra-arterial infusion system. *South Med J* 1962;55:230-2.
226. Urschel HC, Finney JW, Morale AR, et al: *Cardiac Resuscitation with Hydrogen Peroxide*. *Circ* 1965; 31(suppl 11): 11 - 21.
227. Finney JW, Urschel HC, Balla GA, et al: *Protection of the Ischemic Heart with DMSO alone or DMSO with Hydrogen Peroxide*. *Ann NY Acad Sci* 1967; 151: 231 - 241
228. Balla GA, Finney JW, Aronof BL, et al: *Use of Intravenous Hydrogen Peroxide to Promote Wound Healing*. *Am J Surg* 1964: 108: 621 - 629.
229. Balas, E.A. 2001. Information Systems Can Prevent Errors and Improve Quality. *Journal of the American Medical Informatics Association* 8 (4):398-9.
230. National Institute of Medicine Report, 2003b
231. BILL NUMBER: AB 592 AMENDED BILL TEXT; AMENDED IN ASSEMBLY APRIL 4, 2005, INTRODUCED BY Assembly Member Yee FEBRUARY 17, 2005. An act to amend Section 2234.1 of the Business and Professions Code, relating to healing arts.
232. The Principals of Medical Ethics adopted by the American Medical Association in 1980
233. Vesna Vujic´ a Stanislava Stanojevic´ b Mirjana Dimitrijevic´ b Methionine-Enkephalin Stimulates Hydrogen Peroxide and Nitric Oxide Production in Rat Peritoneal Macrophages: Interaction of Ì, % and Opioid Receptors. *Neuroimmunomodulation* 2004;11:392-403
234. Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, Shacter E, Levine M. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. *Proc Natl Acad Sci U S A*. 2005 Sep 20;102(38):13604-9. Epub 2005 Sep 12.
235. Heuser et al. Enhancement of Natrual Killer Cell Activity and T and B Cell Funciton by Buffered Viatmin C in Patients Exposed to Toxic Chemical: The role of Protein Kinase-C *Immunopharmacology and Immunotoxicology* 19(3), 291-312 (1997)
236. Munns SE; Lui JK; Arthur PG. Mitochondrial hydrogen peroxide production alters oxygen consumption in an oxygen-concentration-dependent manner. *Free Radic Biol Med* 2005 Jun 15;38(12):1594-603
237. Yada et al. Hydrogen Peroxide, an Endogenous Endothelium Derived Hyperpolarizing Factor, Plays and important role in Coronary autoregualtion in Vivo. *Circulation* 2003;107:1040-1045.
238. Ichise M, Salit IE, Abbey SE, Chung DG, Gray B, Kirsh JC, Freedman M. Assessment of regional cerebral perfusion by 99Tcm-HMPAO SPECT in chronic fatigue syndrome. *Nucl Med Commun*. 1992 Oct;13(10):767-72.

239. Machale S et al. Cerebral perfusion in chronic fatigue syndrome and depression. *The British Journal of Psychiatry* (2000) 176: 550-556
240. Vojdani A et al. Enhancement of Human Natural Killer Cytotoxic Activity by Vitamin C in Pure and Augmented Formulation. *Journal of Nutritional & Environmental Medicine* (1997) 7, 187-195.
241. Graham J. Chronic Fatigue syndromes- A review. *Journal of Australian College of Nutritional & Environmental Medicine* Vol. 20 No. 2; August 2001: pages 19-28
242. Lindman R, Hagberg M, Bengtsson A, et al. Capillary structure and mitochondrial volume density in the trapezius muscle of Chronic Trapezius Myalgia, Fibromyalgia and healthy subjects. *J Musculoskeletal Pain* 3(3) 1995, 5-22.
243. Jeschonneck M, Grohmann G, Hein G, Sprott H. Abnormal microcirculation and temperature in skin above tender points in patients with fibromyalgia. *Rheumatology (Oxford)* 39(8), Aug, 2000, 917-21.
244. Finney JW et al. Protection of the Ischemic Heart with DMSO Alone or DMSO with Hydrogen Peroxide. *Annals New York Academy of Sciences*
245. Urshel HC et al. Cardiac Resuscitation with hydrogen peroxide. *Circulation*
246. Rowen RJ. Ultraviolet Blood Irradiation Therapy (Photo-Oxidation) The Cure That Time Forgot. *Int J. Biosocial Med Research* Vol. 14(2) 115-32, 1996.
247. Frick, G., A Linke: *Die Ultraviolet bestrahlung des Blutes*, ihre Entwicklung und derzeitiger Stand., Zschr.arztl., Forth. 80, 1986
248. Tetsuo M et al. Induction of Interferon-gamma production by Human Natural Killer Cells Stimulated by Hydrogen Peroxide. *Journal of Immunology* 1985;134:2449-32.
249. Gaffney F et al. Hydrogen Peroxide contrast Echocardiography. *American Journal Cardiolgoy* 1983;52:607-9
250. Zanichelli D et al. Inhibition of *Staphylococcus aureus* by Oleuropein Is Mediated by Hydrogen Peroxide. *Journal of Food Protection*, Vol. 68, No. 7, 2005, Pages 1492-1496
251. Jay BE, Finney JW, Balla GA, et al: *The Supersaturation of Biologic Fluids with Oxygen by the Decomposition of Hydrogen Peroxide*. *Texas Repts Biol and Med* 1964; 22: 106 - 109.
252. Mallams JT, Finney JW, Balla GA. The use of hydrogen peroxide as a source of oxygen in a regional intra-arterial infusion system. *South Med J* 1962;55:230-2.
253. Dylewski J et al. Absence of detectable IgM antibody during cytomegalovirus disease in patients with AIDS. *New England Journal of Medicine* 1985:309:493.
254. Furuichi T et al. Generation of hydrogen Peroxid During brief Oxygen-Glucose deprivation Induces Preconditioining Neuronal Protection in Primary Cultured Neurons. *Journal of Neuroscience research* 2005:79:816-24.
255. Robert E. Hirschtick, MD; Susan E. Dyrda, MD; and LoAnn C. Peterson, MD Death from an Unconventional Therapy for AIDS. *Annals of Internal Medicine*. 15 April 1994;120;8:694
256. Medwatch: The FDA Medical Products Reporting Program COPAXONE (glatiramer acetate) Injection. July 6, 2000.
257. Physicians Desk Reference. Medical Economics Thomson Healthcare, 2005
258. Finney JW, Jay BE, Race GJ, et al: *Removal of Cholesterol and Other Lipids from Experimental Animal and Human Atheromatous Arteries by Dilute Hydrogen Peroxide*. *Angiology* 1966; 17: 223 – 228

259. Finney JW, Balla GA, Race GJ, et al: *Peripheral Blood Changes in Humans and Experimental Animals Following the Infusion of Hydrogen Peroxide into the Carotid Artery*. *Angiology* 1965; 16: 62 - 66.
260. Wand et al. Contrast Echocardiography with Hydrogen Peroxide. *Chinese Medical Journal* 1979;92():595-9.
261. Walrand S et al. Specific and nonspecific immune response to fasting and refeeding differ in healthy young adult and elderly persons. *Am J clin Nutr* 2001;74:670-8.
262. Haw C, Stubbs J. A survey of off-label prescribing for inpatients with mild intellectual disability and mental illness. *J Intellect Disabil Res*. 2005 Nov;49(Pt 11):858-64.
263. Haw C, Stubbs J. A survey of the off-label use of mood stabilizers in a large psychiatric hospital. *J Psychopharmacol*. 2005 Jul;19(4):402-7.
264. Kogut SJ, Yam F, Dufresne R. Prescribing of antipsychotic medication in a Medicaid population: use of polytherapy and off-label dosages. *J Manag Care Pharm*. 2005 Jan-Feb;11(1):17-24.
265. M. Karaca, U.Y. Bilgin, and M. Akar Dimethyl Sulfoxide Lowers ICP After Closed Head Trauma. *Eur J Clin Pharmacol* (1991) 40:113-114003169709100019B.
266. Walter F, Tanabe C, Paxton H (1983) Treatment of elevated intracranial pressure with dimethyl sulfoxide. *Ann NY Acad Sci* 411: 286-292.
267. Marshall LF, Camp P, Bowers S (1984) Dimethyl sulfoxide for the treatment of intracranial hypertension. A preliminary trial. *J Neurosurg* 14: 659-663.
268. Mullan S, Jafar I, Hanlon K, Brown F (1980) Dimethyl sulfoxide in the management of postoperative hemiplegia. In: Wilkins RH (ed) *Cerebral arterial spasm*. William and Wilkins. Baltimore, pp 646-653.
269. de la Torre JC, Rowed D, Kawanaga H, Mullan S (1973) Dimethyl sulfoxide in the treatment of experimental brain compression. *J Neurosurg* 38: 345-354.
270. James HE, Camp P, Harbaugh R, Marshall L (1983) Comparison of the effects of DMSO and pentobarbitone on experimental brain oedema. *Acta Neurochir* 60: 245-255.
271. de la Torre JC (1983. ed) Biological actions and medical applications of dimethyl sulfoxide. *Ann NY Acad Sci* 411: 1-403.
272. Brown FD, Johns L, Mullan S (1983) Dimethyl sulfoxide therapy following penetrating brain injury. *Ann NY Acad Sci* 411: 245-252.
273. James RE, Camp P, Harbaugh R, Marshall L, Werner R (1982) Comparison of the effects of DMSO and pentobarbitone on experimental brain oedema. *Acta Neurochir* 60: 245-255
274. de la Torre JC (1983) Role of dimethyl sulfoxide in prostaglandin-thromboxane and platelet systems after cerebral ischemia. *Ann NY Acad Sci* 411: 293-308.
275. Park DA (1983) Role of oxygen-derived free radicals in digestive tract diseases. *Surgery* 94: 415-422.
276. Ojo-Amaize EA, Conley EJ, Peter JB. Decreased natural killer cell activity is associated with severity of chronic fatigue immune dysfunction syndrome. *Clin Infect Dis*. 1994 Jan;18 Suppl 1:S157-9.
277. Gin W, Christiansen FT, Peter JB. Immune function and chronic fatigue syndrome. *Med J Aust*

1989;151:117-8.

278. Caligiuri M, Murray C, Buchwald D, et al. Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. *J Immunol* 1987;139:3306-13.
279. Stricker RB, Winger EE. Decreased CD57 lymphocyte subset in patients with chronic Lyme disease. *Immunol Lett.* 2001 Feb 1;76(1):43-8.
280. Klimas N, Salvato F, Morgan R, Fletcher M. Immunologic Abnormalities in Chronic Fatigue Syndrome. *Journal of Clinical Microbiology*, June 1990:1403-10.
281. Lusso P, Malnati M, Garzino-Demo A et al. Infection of natural killer cells by human herpesvirus 6. *Nature* 1993; 362:458-462.
282. De Meirleir K et al. A 37 kDa 2-5A binding protein as a potential biochemical marker for chronic fatigue syndrome. *Am J Med.*2000; 108(2):99-105.
283. Vojdani et al. RNase L in Health and Disease: What Did We Learn Recently? *Journal of Chronic Fatigue Syndrome*, Vol. 11(2) 2003, pp. 97-109.
284. Suhadolnik RJ et al. Changes in the 2-5A synthetase/RNase L antiviral pathway in a controlled clinical trial with poly(I) poly(C12U) in chronic fatigue syndrome. *In Vivo.* 1994; 8:599-604.
285. Suhadolnik RJ et al. Upregulation of the 2-5A synthetase/ RNase L antiviral pathway associated with chronic fatigue syndrome. *Clin Infect Dis.*1994; 18:S96-S104.
286. Suhadolnik RJ et al. Biochemical evidence for a novel low molecular weight 2-5A-dependent RNase L in chronic fatigue syndrome. *J Interferon & Cytokine Res.*1997; 17:377-85.
287. Suhadolnik RJ et al. Biochemical dysregulation of the 2-5A synthetase/RNase L antiviral defense pathway in chronic fatigue syndrome. *J Chronic Fatigue Syndrome.*1999; 5:223-242.
288. Vojdani A, Choppa PC, Lapp CW. Downregulation of RNase L inhibitor correlates with upregulation of interferon-induced proteins (2-5A synthetase and RNase L) in patients with chronic fatigue immune dysfunction syndrome. *J Clin Lab Immunol.* 1998; 50:1-16.
289. Courtney CH et al. Authors' Response: HPOA Axis Testing after Pituitary Surgery. *Journal of clinical Endocrinology and Metabolism* 2005;90:6744.
290. Cho et al. A strong association between thyrotropin receptor-blocking antibody-positive atrophic autoimmune thyroiditis and HLA-DR8 and HLA-DQB1 0302 in Koreans. *J. Endocrinology and Metabolism* 2001; Vol/Issue: 77:3
291. Chopra I. A Study of Extrathyroidal conversion of Thyroxine to T3 In Vitro. *Endocrinology* 1977;101:453-64.
292. Robin P. Peeters, Pieter J. Wouters, Hans van Toor, Ellen Kaptein, Theo J. Visser, and Greet Van den Berghe. Serum 3,3',5'-Triiodothyronine (rT3) and 3,5,3'-Triiodothyronine/rT3 Are Prognostic Markers in Critically Ill Patients and Are Associated with Postmortem Tissue Deiodinase Activities. *The Journal of Clinical Endocrinology & Metabolism* 90(8):4559-4565
293. Annewieke W. van den Beld, Theo J. Visser, Richard A. Feelders, Diederick E. Grobbee, and Steven W. J. Lamberts Thyroid Hormone Concentrations, Disease, Physical Function, and Mortality in Elderly Men. *J Clin Endocrinol Metab* 2005 90: 6403-6409; September 20 2005.
294. Stefano Mariotti. Editorial: Thyroid Function and Aging: Do Serum 3,5,3'-Triiodothyronine and Thyroid-Stimulating Hormone Concentrations Give the Janus Response? *J Clin Endocrinol Metab* 2005 90: 6735-6737.

295. Robin P. Peeters, Serge van der Geyten, Pieter J. Wouters, Veerle M. Darras, Hans van Toor, Ellen Kaptein, Theo J. Visser, and Greet Van den Berghe. Tissue Thyroid Hormone Levels in Critical Illness. *J Clin Endocrinol Metab* 2005 90: 6498-6507.
296. K Arikawa, Y Ichikawa, T Yoshida, T Shinozawa, M Homma, N Momotani and K Blocking type antithyrotropin receptor antibody in patients with nongoitrous hypothyroidism: its incidence and characteristics of action. *Journal of Clinical Endocrinology & Metabolism*, Vol 60, 953-959.
297. Wikland B, Lowhagen T, Sandberg PO. Fine needle aspiration cytology of the thyroid in chronic fatigue. *Lancet* 2001;357:956-57.
298. Bo Wikland, P O Sandberg, Hans Wallinder Subchemical Hypothyroidism. *THE LANCET* • Vol 361 • April 12, 2003
299. Apurva K. Srivastava; Elizabeth L. Vliet; E. Michael Lewiecki; Michael Maricic; Alex Abdelmalek; Oscar Gluck; David J. Baylink . Clinical Use of Serum and Urine Bone Markers in the Management of Osteoporosis. *Curr Med Res Opin.* 2005;21(7):1015-1026
300. Lloyd AR, Wakefield D, Boughton CR, et al: Immunological abnormalities in the chronic fatigue syndrome. *Med J Aust* 151:122-124, 1989
301. Roberto Patarca, Timothy Mark, Mary Ann Fletcher and Nancy Klimas Review: Immunology of Chronic Fatigue Syndrome *Journal of Chronic Fatigue Syndrome* 2000; 6(3/4): 69-107.
302. Buchwald D, Komaroff AL: Review of laboratory findings for patients with chronic fatigue syndrome. *Rev Infect Dis* 13(1):S12-S18, 1991
303. DuBois RE: Gamma globulin therapy for chronic mononucleosis syndrome. *AIDS Res Hum Retroviruses* 2(1):S191-S195, 1986
304. Wakefield D, Lloyd A, Brockman A: Immunoglobulin subclass abnormalities in patients with chronic fatigue syndrome. *J Pediatr Infect Dis* 9(8):S50-S53, 1990
305. Read R, Spickett G, Harvey J, et al: IgG1 subclass deficiency in patients with chronic fatigue syndrome. *Lancet* 1:241-242, 1988.
306. Lloyd A, Hickie I, Wakefield D, et al: A double-blind, placebo-controlled trial of intravenous immunoglobulin therapy in patients with chronic fatigue syndrome. *Am J Med* 89:561-568, 1990
307. Peterson PK, Shepard J, Macres M, et al: A controlled trial of intravenous immunoglobulin G in chronic fatigue syndrome. *Am J Med* 89:554-560, 1990
308. Rowe KS: Double-blind randomized controlled trial to assess the efficacy of intravenous gammaglobulin for the management of chronic fatigue syndrome in adolescents. *Journal of Psychiatric Research* 31(1):133-147, 1997
309. Straus SE: Intravenous immunoglobulin treatment for the chronic fatigue syndrome. *Am J Med* 89:551-553, 1990
310. Cox IM, Campbell MJ, Dowson D. Red blood cell magnesium and chronic fatigue syndrome. *Lancet* 1991; 337: 757-60.
311. H. Harrison^{1,2}, L. Berg², and D. Berg². Polygenic Contributions of Procoagulant Genetic Factors in Chronic Fatigue Syndrome and Related Chronic Illnesses. *Genetics in Medicine*, May, 2002
312. D Berg, LH Berg, J Couvaras Is CFS/FM Due to an Undefined Hypercoagulable State Brought on by Immune Activation of Coagulation? Does Adding Anticoagulant therapy Improve CFS/FM Patient? Presentation: American Association Chronic Fatigue Syndrome, Oct, 98.

313. D Berg, LH Berg, J Couvaras & H Harrison: Chronic Fatigue Syndrome (CFS) &/or Fibromyalgia (FM) as a Variation of Antiphospholipid Antibody Syndrome (APS): An Explanatory Model and Approach to Laboratory Diagnosis. *Blood Coagulation and Fibrinolysis*. 1999,10:p 1 - 4.
314. Hannan et al. Activation of the coagulation system in Gulf War Illness: a potential pathophysiologic link with chronic fatigue syndrome. A laboratory approach to diagnosis. *Blood Coagulation and Fibrinolysis* 2000;11:673-8
315. Berg et al. use of sensitive markers of coagulation activation to monitor low-dose heparin therapy in patients with chronic Fatigue syndrome and fibromyalgia (CFS/FM). *Clinical Chemistry* 2003;49:A9
316. Bolours S, et al. Testosterone therapy in women: a review. *Int J Impot Res*, 2005 Sep-Oct; 17(5):399-408
317. Tennant F. Hormone Treatments in Chronic and Intractable Pain. *Practical Pain Management* 2005.
318. McNett M et al. The Role of Candida in Fibromyalgia. Latest 21st Century Advances in the Diagnosis & Treatment of Fibromyalgia, Chronic Fatigue Syndrome and Related Illnesses. Los Angeles, CA Sept 19-21, 2002.
319. Martin W.J. Viral infection in CFS patients. In "The Clinical and Scientific Basis of Myalgic Encephalomyelitis Chronic Fatigue Syndrome." Byron M. Hyde Editor. Nightingdale Research Foundation Press. Ottawa Canada pp 325-327, 1992.
320. Martin W.J. Detection of viral related sequences in CFS patients using the polymerase chain reaction.in "The Clinical and Scientific Basis of Myalgic Encephalomyelitis Chronic Fatigue Syndrome." Byron M. Hyde Editor. Nightingdale Research Foundation Press. Ottawa Canada pp 278-283, 1992.
321. Martin WJ, Zeng LC, Ahmed K, Roy M. Cytomegalovirus-related sequences in an atypical cytopathic virus repeatedly isolated from a patient with the chronic fatigue syndrome. *Am. J. Path.* 145: 441-452, 1994.
322. Martin W.J. Stealth viruses as neuropathogens. College of American Pathologist's publication "CAP Today" 8 67-70, 1994
323. Martin WJ. Stealth virus isolated from an autistic child. *J. Aut. Dev. Dis.* 25:223-224,1995
324. Martin WJ, Ahmed KN, Zeng LC, Olsen J-C, Seward JG, Seehrai JS. African green monkey origin of the atypical cytopathic 'stealth virus' isolated from a patient with chronic fatigue syndrome. *Clin. Diag. Virol.* 4: 93-103, 1995.
325. Martin WJ. Severe stealth virus encephalopathy following chronic fatigue syndrome-like illness: Clinical and histopathological features. *Pathobiology* 64:1-8, 1996.
326. Martin WJ. Stealth viral encephalopathy: Report of a fatal case complicated by cerebral vasculitis. *Pathobiology* 64:59-63, 1996.
327. Martin WJ. Simian cytomegalovirus-related stealth virus isolated from the cerebrospinal fluid of a patient with bipolar psychosis and acute encephalopathy. *Pathobiology* 64:64-66, 1996. 10. Gollard RP, Mayr A, Rice DA, Martin WJ. Herpesvirus-related sequences in salivary gland tumors. *J. Exp. Clin. Can. Res.* 15: 1-4, 1996.
328. Martin WJ. Genetic instability and fragmentation of a stealth viral genome. *Pathobiology* 64:9-17, 1996. 12. Martin WJ, Glass RT. Acute encephalopathy induced in cats with a stealth virus

- isolated from a patient with chronic fatigue syndrome. *Pathobiology* 63: 115-118, 1995.
329. Martin WJ. Detection of RNA sequences in cultures of a stealth virus isolated from the cerebrospinal fluid of a health care worker with chronic fatigue syndrome. *Pathobiology* (in press)
 330. Shifren, J. Position Statement: The role of testosterone therapy in postmenopausal women: position statement of The North American Menopause Society *Menopause: The Journal of The North American Menopause Society* Vol. 12, No. 5, pp. 497-511.
 331. Miler K et al. Measurement of Free Testosterone in Normal Women and Women with Androgen Deficiency: Comparison of Methods. *The Journal of Clinical Endocrinology & Metabolism* 89(2):525–533
 332. Schneider ME. Testosterone May Help Some Post Menopause. *Family Practice News*; Nov 1, 2005;5.
 333. Sherwin BB, Gelfand MM, Brender W. Androgen enhances sexual motivation in females: a prospective, crossover study of sex steroid administration in surgical menopause. *PsychosomMed* 1985; 47:339-351.
 334. Burger HG, Hailes J, Nelson J, Menelaus M. Effect of combined implants of estradiol and testosterone on libido in postmenopausal women. *BMJ* 1987;294:936-937
 335. Gerhard Rf et al. Clinical Correlates of Infection with Human Herpesvirus-6. *In vivo* 1994; 8:457-86.
 336. Levine PH et al. *The Postinfectious Chronic Fatigue Syndrome*. Humana Press, Clifton NJ 1989; 405-38.
 337. Krueger GRF et al. Overview of immunopathology of chronic active herpesvirus infection. *J Virol Methods* 1988;21:11-18
 338. Ablashi DV et al. Human Herpes virus and chronic fatigue syndrome. *Canad Dis Weekly Rep* 1991;17S1:33-40
 339. Albashi DV et al. human B lymphotropic virus (human herpesvirus-6). *J Virol Methods* 1988; 21:29-48.
 340. Josephs SF et al HHV-6 reactivation in chronic fatigue syndrome. *Lancet* 1991;1346-7
 341. Wolf F, Smythe HA et al. American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. *Arthritis Rheum* 1990; 33:160-72.
 342. Teitelbaum J. PreAmerican Association for CFS/FMS 7th International Conference. A clinically focused workshop on Effective CFS/Fibromyalgia Therapies. October 7, 2004 Madison, Wisconsin
 343. Teitelbaum J. Effective Treatment of Chronic Fatigue Syndrome, Pain and Fibromyalgia - A Double-blind Study 12th Annual World Congress on Anti-Aging Medicine, Las Vegas, NV 2005
 344. Teitelbaum J. Latest 21st Century Advances in the Diagnosis & Treatment of Fibromyalgia, Chronic Fatigue Syndrome and Related Illnesses. Los Angeles, CA Sept 19-21, 2002.
 345. Ali M et al. Efficacy of ecologic-integrative management; protocols for reversal of fibromyalgia. *J Integrative Medicine* 1999;3:48-64
 346. Robert S. Katz, 1 Frederick Wolfe, 2 and Kaleb Michaud 3 Fibromyalgia Diagnosis A Comparison of Clinical, Survey, and American College of Rheumatology Criteria. *Arthritis & Rheumatism* Vol. 54, No. 1, January 2006, pp 169–176

347. Wolfe F. Diagnosis of fibromyalgia. *J Musculoskel Med* 1990;7:53–69.
348. Aaron LA, Buchwald D. Chronic diffuse musculoskeletal pain, fibromyalgia and co-morbid unexplained clinical conditions. *Best Pract Res Clin Rheumatol* 2003;17:563–74.
349. Clauw DJ, Crofford LJ. Chronic widespread pain and fibromyalgia: What we know, and what we need to know. *Best Pract Res Clin Rheumatol* 2003;17:685–701.
350. Crofford LJ, Clauw DJ. Fibromyalgia: where are we a decade after the American College of Rheumatology classification criteria were developed? [editorial]. *Arthritis Rheum* 2002;46:1136–8.
351. Russell J M Lane, Michael C Barrett, David Woodrow, Jill Moss, Robert Fletcher, Leonard C Archard. Muscle fibre characteristics and lactate responses to exercise in chronic fatigue syndrome *J Neurol Neurosurg Psychiatry* 1998;64:362–367
352. Goldenberg DL. Fibromyalgia syndrome a decade later: what have we learned? *Arch Intern Med* 1999;159:777–85.
353. Buchwald D et al. Comparison of patients with chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivities. *Archives of Internal Medicine* 1994;154:2049-2053.
354. Goldenberg DL et al. High frequency of fibromyalgia in patients with chronic fatigue syndrome seen in primary care practice. *Arthritis and Rheumatism* 1990;33:381-7.
355. Behan W. et al. Mitochondrial abnormalities in post viral fatigue syndrome. *Acta Neuropathology* 1991;83:61-5.
356. Niteesh. C et al. Systematic Review: The relationship between Clinical experience and quality of health care. *Annals of Internal Medicine*
357. Bennett. Growth Hormone in Musculoskeletal Pain States. *Current Rheumatology Reports* 2004, 6:266-273.
358. Lloyd A et al. A Double-blind, Placebo-controlled Trial of Intravenous Immungobulin therapy I Patients wit Chronic Fatigue Syndrome. *The American Journal of amedicnde*;89:561-9.
359. Rowe K et al. Double-blind Randomized controlled Trial to Assess the Efficacy of Intravenous Gammaglobulin of the Management of Chronic Fatigue syndrome. *J psyciat Res* 1997;31:133-45.
360. Ryser CA. Innovative Diagnosis and Treatment of Chronic Illness. *Anti-Aging Therapeutics* 2003;5:465-86.
361. American Physiological Society annual meeting, 2003
<http://www.webmd.com/content/Article/63/72082.htm>
362. Streeten, David H. P., et al. "The roles of orthostatic hypotension, orthostatic tachycardia, and subnormal erythrocyte volume in the pathogenesis of the chronic fatigue syndrome." *The American Journal of the Medical Sciences*, July 2000, vol. 320, no. 1; 1-8.
363. Lerner, A. M., Zervos, M., Dworkin H.J., et al. "New cardiomyopathy: a pilot study of intravenous gancyclovir in a subset of the chronic fatigue syndrome." *Inf Dis in Clin Pract*, 1997; 6:239-43.

364. Lerner, A. M., Goldstein, J., O'Neill W., et al. "Cardiac involvement in patients with chronic fatigue syndrome as documented with Holter and biopsy data in Birmingham, Michigan, 1991-1993." *Inf Dis in Clin Pract*, 1997; 6:327-333.
365. Lerner, A.M. "Editorial Response: Microbial Persistence and Idiopathic Dilated Cardiomyopathy." *Clinical Infectious Diseases* (1999):29:526-7.
366. Chris. J. Malkin, et al. "Testosterone Therapy in Men with Moderate Severity Heart Failure: a Double-blind Randomized Placebo Controlled Trial," *Eur Heart J*, 2006; 27(1): 57-64.
367. Streeten, David H. P., and Bell, D. "Circulating blood volume in chronic fatigue syndrome." *JCFS*, vol. 4 (1) 1998; 3-11.